Cullinan director granted 21,781 stock options

Cullinan Therapeutics director Mittie Doyle received a new stock option grant.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cullinan Therapeutics director Mittie Doyle received a new stock option grant. The award covers 21,781 shares of Common Stock at an exercise price of $13.55 per share. According to the terms, the option vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director.

Insider Trade Summary

Grant/Award: 21,781 shares

Grant/Award 1 txn

Insider Doyle Mittie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	21,781	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,781 contracts (Direct)

Footnotes (1)

F1. The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

Key Figures

Option grant size: 21,781 shares Exercise price: $13.55 per share Shares after transaction: 21,781 options +1 more

4 metrics

Option grant size 21,781 shares Stock Option (Right to Buy) underlying common shares

Exercise price $13.55 per share Conversion or exercise price of the stock option

Shares after transaction 21,781 options Total derivative shares held following the grant

Vesting trigger date June 16, 2027 Full vesting or earlier at next annual meeting, subject to service

Key Terms

Stock Option (Right to Buy), exercise price, underlying security, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 13.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cullinan Therapeutics (CGEM) report for Mittie Doyle?

Cullinan Therapeutics reported that director Mittie Doyle received a stock option grant for 21,781 shares. The option is a compensation-related award, not an open-market trade, and gives her the right to buy common shares at a fixed exercise price.

How many shares are covered by Mittie Doyle’s new CGEM stock option grant?

The new stock option grant to Mittie Doyle covers 21,781 underlying shares of Cullinan Therapeutics common stock. This entire amount was reported as held following the transaction, reflecting a single compensation grant rather than multiple transactions.

What is the exercise price of Mittie Doyle’s Cullinan Therapeutics stock options?

Mittie Doyle’s newly granted stock options have an exercise price of $13.55 per share. This price is the fixed amount she must pay per share to exercise the options and acquire Cullinan Therapeutics common stock in the future, after vesting.

When do Mittie Doyle’s Cullinan Therapeutics stock options vest?

The stock options granted to Mittie Doyle vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting. Vesting remains subject to her continued service as a director through the applicable vesting date.

Is Mittie Doyle’s Form 4 transaction in CGEM a market purchase or sale?

The reported Form 4 transaction is a grant of stock options, not a market purchase or sale. It is classified as an acquisition by grant or award, reflecting director compensation rather than an open-market trade in Cullinan Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 05:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last)

(First)

(Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.55	06/16/2026		A		21,781		⁽¹⁾	06/16/2026	Common Stock	21,781	$0	21,781	D

Explanation of Responses:

1. The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR